Use of the MIA for Adjuvant Therapy Prediction Tool (‘Calculator’) is subject to the following:
The Calculator has been developed by Melanoma Institute Australia (‘MIA’),
based on a published risk prediction model (see References).
This tool has been designed only for use by clinicians in relation to patients with resected stage III melanoma.
It does not apply to patients with recurrent disease after prior adjuvant therapy, nor to those treated with neoadjuvant therapy.
Any clinician who uses the Calculator agrees and acknowledges that:
This tool is intended for educational and clinical support purposes only.
It is not designed for treatment selection.
Estimates are based on adjuvant trial data and do not account for very early post-surgical recurrences
(patients who relapsed before trial randomisation are not included).
DMFS estimates from COMBI-AD have a known methodological limitation due to the censoring strategy used in that trial.
The risk estimate generated by the Calculator must be interpreted in relation to its clinical significance for the patient in question.
The information provided by the Calculator must only be used as a general guide.
MIA gives no warranties, nor makes any representations to any clinician or patient regarding the accuracy, completeness, timeliness or usefulness of any estimate or risk range generated by the Calculator; and
MIA will have no liability to the clinician or any patient for the consequences of any treatment decision made - or any action taken or not taken - by the clinician or their patient following use of the Calculator.
